NeurogesX Inc. (NGSX) confirmed that the Division of Anesthesia, Analgesia and Addiction Products or DAAAP of the U.S. Food and Drug Administration has scheduled an Anesthetic and Analgesic Drug Products Advisory Committee or AADPAC meeting on February 9, 2012, to review NeurogesX' supplemental New Drug Application or sNDA for Qutenza (capsaicin) 8% patch for the management of neuropathic pain associated with HIV-associated peripheral neuropathy or HIV-PN.
Qutenza is currently approved in the United States for the management of neuropathic pain associated with postherpetic neuralgia.
NeurogesX announced the FDA acceptance of the sNDA filing on November 14, 2011, and noted the Agency's goal is to review and act on the sNDA by March 7, 2012 under the Prescription Drug User Fee Act IIII.
For comments and feedback: editorial@rttnews.com